Acquisition of Boucart Medical SRL

Belgium based supplier of GI Endoscopy products complements Albyn Medical’s product range

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, is pleased to announce the acquisition of Boucart Medical SRL (“Boucart Medical”), the largest independent supplier of gastrointestinal (GI”) endoscopy consumables in Belgium and Luxembourg, for an initial consideration of €4.5 million in cash (subject to closing adjustments for cash, debt and working capital) plus up to €0.5 million of performance related consideration payable in cash over the next two years.

Boucart Medical, founded in 1991, is a well-established supplier of medical devices for the GI market, distributing third-party products to hospitals across Belgium and Luxembourg for 30 suppliers. Boucart Medical distributes a range of GI products similar to that distributed by Albyn Medical S.L. (“Albyn Medical”) which was acquired by Creo in July this year, and has a particular focus on introducing innovative devices to its hospital network.

For the year ended 31 December 2019, Boucart Medical recorded an EBITDA of €0.7 million and PBT of €0.6 million. Both revenues and earnings have grown each year over the last five-year period. As at 31 December 2019, Boucart Medical had gross assets of €2 million and employs 10 staff predominantly in sales and marketing functions.

Following the acquisition of Boucart Medical, the Company now has a direct sales presence in the key markets of Spain, France, Germany, the UK, the USA, Belgium and Luxembourg providing Creo with a strong commercial platform to facilitate the roll-out of its full suite of CE marked GI advanced energy devices.

Boucart Medical is being acquired by Creo’s subsidiary Albyn Medical.

For further information on Boucart Medical visit: www.boucartmedical.com/en

Posted 03/11/2020

For press enquiries please contact media@creomedical.com. For all other enquiries please visit our Contact page.

Further news

15 May 2024

Full results - Final Results Strong revenue growth and significant commercial progress (9th May 2024)

Read

13 May 2024

Directorate Changes - May 2024

Read

07 May 2024

Creo Medical receives King’s Award for Enterprise in Innovation

Read

02 May 2024

MicroBlate Flex in new clinical trial at Royal Brompton Hospital

Read

24 April 2024

NHS Supply Chain real-world data demonstrates substantial cash savings

Read

19 March 2024

Welsh Labour Leader visits Creo’s facilities

Read

05 February 2024

Strategic Collaboration with Khalifa University of Science and Technology, Abu Dhabi

Read

31 January 2024

Roll-out of Speedboat® UltraSlim reaches Asia Pacific

Read

10 January 2024

First Use of Speedboat® UltraSlim in Latin America

Read

13 December 2023

First European Speedboat® UltraSlim procedure marks early commercial launch

Read